Publications by authors named "Hye-In Sim"

Claim this Profile
E
Erratum to: Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2.
Hye-In Sim, Yunju Jo, Hyejin Ahn, Juyeon Hong, Hye-Bin Kim

BMB Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2.
Hye-In Sim, Yunju Jo, Hyejin Ahn, Juyeon Hong, Hye-Bin Kim

BMB Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.
Yunju Jo, Hye-In Sim, Bohwan Yun, Yoon Park, Hyung-Seung Jin

Exp Mol Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.
Dong-Hee Lee, Hyejin Ahn, Hye-In Sim, Eunji Choi, Seunghyun Choi

J Exp Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.
Dong-Hee Lee, Yu-Jeong Jeong, Ju-Young Won, Hye-In Sim, Yoon Park

Biomedicines· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis